Jefferies Group Reiterates “$80.00” Price Target for Bluebird Bio Inc. (BLUE)
A number of other analysts have also recently weighed in on the stock. Roth Capital started coverage on shares of Bluebird Bio in a report on Thursday, September 22nd. They set a buy rating and a $87.00 price objective on the stock. Goldman Sachs Group Inc. raised shares of Bluebird Bio from a buy rating to a conviction-buy rating and set a $135.00 price objective on the stock in a report on Thursday, September 15th. Cantor Fitzgerald cut shares of Bluebird Bio from a hold rating to a sell rating and cut their target price for the company from $65.24 to $37.00 in a report on Friday, October 14th. Leerink Swann lifted their target price on shares of Bluebird Bio from $67.00 to $80.00 and gave the company an outperform rating in a report on Friday, October 14th. Finally, Maxim Group reaffirmed a buy rating and issued a $85.00 target price (down from $105.00) on shares of Bluebird Bio in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $82.82.
Bluebird Bio (NASDAQ:BLUE) opened at 60.65 on Thursday. The stock’s market capitalization is $2.26 billion. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $90.01. The firm’s 50-day moving average is $55.97 and its 200 day moving average is $53.04.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.82 million. During the same period in the previous year, the business posted ($1.18) EPS. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. Equities analysts expect that Bluebird Bio will post ($7.05) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Jefferies Group Reiterates “$80.00” Price Target for Bluebird Bio Inc. (BLUE)” was originally published by Financial Market News and is owned by of Financial Market News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. and international copyright laws. The original version of this article can be viewed at http://www.financial-market-news.com/jefferies-group-reiterates-80-00-price-target-for-bluebird-bio-inc-blue/1208019/.
In related news, insider Eric Sullivan sold 416 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the sale, the insider now directly owns 5,891 shares in the company, valued at approximately $394,697. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in Bluebird Bio by 37.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 3,365,797 shares of the company’s stock valued at $228,134,000 after buying an additional 921,416 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Bluebird Bio by 143.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 7,800 shares of the company’s stock valued at $528,000 after buying an additional 4,600 shares in the last quarter. Credit Suisse AG raised its stake in Bluebird Bio by 9.3% in the third quarter. Credit Suisse AG now owns 101,322 shares of the company’s stock valued at $6,869,000 after buying an additional 8,656 shares in the last quarter. Chartwell Investment Partners LLC acquired a new stake in Bluebird Bio during the third quarter valued at approximately $2,830,000. Finally, Baker BROS. Advisors LP acquired a new stake in Bluebird Bio during the third quarter valued at approximately $19,923,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.